| Literature DB >> 29546247 |
Andrew D Frugé1, John A Dasher2, David Bryan1, Soroush Rais-Bahrami3, Wendy Demark-Wahnefried1, Gary R Hunter4.
Abstract
BACKGROUND: Obesity and weight gain after the diagnosis of prostate cancer are associated with an increased risk of prostate cancer recurrence and mortality; individualized plans to help prostate cancer survivors maintain or lose weight may be beneficial for recurrence risk reduction. Herein, we explore whether gains in cardiovascular fitness predict successful weight loss in men participating in a weight loss trial (NCT01886677).Entities:
Keywords: Aerobic fitness; Exercise; Obesity; Prostatic neoplasms; Weight loss
Year: 2017 PMID: 29546247 PMCID: PMC5846475 DOI: 10.23937/2378-3419/1410083
Source DB: PubMed Journal: Int J Cancer Clin Res ISSN: 2378-3419
Figure 1Baseline and follow-up VO2submax treadmill tests were completed by men with prostate cancer participating in a presurgical weight loss trial. If 80% of estimated maximum heart rate was not reached in Stage 3, the following stages ensued: Stage 4) 6.44 km/hr, 4% incline; Stage 5) 6.44 km/hr, 8% incline.
Baseline and follow-up measures for men with prostate cancer participating in a presurgical weight loss trial (n = 32).
| Baseline | Follow-up | Change | |
|---|---|---|---|
| Body weight (kg) | 96.4 ± 13.8 | 93.0 ± 13.3 | −3.4 ± 3.9 |
| Body Mass Index (kg/m2) | 31.1 ± 4.4 | 30.0 ± 4.2 | −1.1 ± 1.3 |
| Percent body fat | 36.0 ± 5.5 | 34.6 ± 5.5 | −1.4 ± 1.9 |
| Caloric Intake | 1587 ± 525 | 1298 ± 432 | 289 ± 667 |
| Stage 1 VO2 | 10.1 ± 1.9 | 9.6 ± 2.0 | −0.4 ± 1.7 |
| Stage 2 VO2 | 13.1 ± 2.1 | 12.5 ± 2.2 | −0.5 ± 2.2 |
| Stage 1 HR | 96.1 ± 13.3 | 90.1 ± 13.3 | −6.0 ± 9.9 |
| Stage 2 HR | 106.8 ± 14.2 | 100.1 ± 13.3 | −6.7 ± 10.6 |
| Stage 1% of max HR | 0.601 ± 0.086 | 0.563 ± 0.087 | −0.038 ± 0.062 |
| Stage 2% of max HR | 0.667 ± 0.088 | 0.626 ± 0.086 | −0.041 ± 0.066 |
| Predicted VO2max | 25.0 ± 2.0 | 25.8 ± 2.1 | 0.8 ± 1.5 |
| Predicted Lean mass VO2max | 42.0 ± 1.4 | 41.7 ± 1.4 | −0.3 ± 1.1 |
n = 31 due to no DEXA data;
Average of two-24 hour dietary recalls, n = 28; Stage 1: 3.22 km/hr, no incline; Stage 2: 3.22 km/hr, 4% incline;
p < 0.01;
p < 0.05;
p < 0.001, significant at p < 0.004.
Correlations between weight change, physiological effort and predicted VO2max in men with prostate cancer participating in a presurgical weight loss trial (n = 32).
| Change in weight (kg) | Baseline HR @ Stage 1 | Baseline HR @ Stage 2 | Baseline VO2max | Baseline lean mass VO2max | Change in HR @ Stage 1 | Change in HR @ Stage 2 | Change in predicted VO2max | Change in lean mass VO2max | |
|---|---|---|---|---|---|---|---|---|---|
| Change in weight (kg) | 1 | −0.260 | −0.380 | 0.406 | −0.039 | 0.393 | 0.576 | −0.241 | −0.058 |
| Baseline HR @ Stage 1 | 1 | 0.943 | −0.818 | 0.375 | −0.370 | −0.282 | −0.009 | −0.063 | |
| Baseline HR @ Stage 2 | 1 | −0.791 | 0.503 | −0.396 | −0.453 | −0.033 | −0.107 | ||
| Baseline Predicted VO2max | 1 | 0.136 | 0.356 | 0.341 | −0.166 | −0.101 | |||
| Baseline lean mass VO2max | 1 | −0.134 | −0.251 | −0.264 | −0.294 | ||||
| Change in HR @ Stage 1 | 1 | 0.826 | −0.154 | −0.078 | |||||
| Change in HR @ Stage 2 | 1 | −0.175 | −0.059 | ||||||
| Change in predicted VO2max | 1 | 0.975 |
Stage 1: 3.22 km/hr, no incline; Stage 2: 3.22 km/hr, 4% incline;
n = 31 due to no DEXA data;
p < 0.01;
p < 0.05;
p < 0.001.
Figure 2Weight loss correlates with decrease in heart rate in submaximal treadmill test Stage 2 TT (p = 0.0006) in men with prostate cancer participating in a presurgical weight loss trial (n = 32).
Correlations between weight change and physiological effort as a percent of estimated maximum heart rate in men with prostate cancer participating in a presurgical weight loss trial (n = 32).
| Change in weight (kg) | Baseline % of Max HR @ Stage 1 | Baseline % of Max HR @ Stage 2 | Change in % of Max HR @ Stage 1 | Change in % of Max HR @ Stage 2 | |
|---|---|---|---|---|---|
| Change in weight (kg) | 1 | −0.270 | −0.398 | 0.394 | 0.583 |
| Baseline % of Max HR @ Stage 1 | 1 | 0.947 | −0.351 | −0.236 | |
| Baseline % of Max HR @ Stage 2 | 1 | −0.385 | −0.410 | ||
| Change in % of Max HR @ Stage 1 | 1 | 0.823 |
Stage 1: 3.22 km/hr, no incline; Stage 2: 3.22 km/hr, 4% incline;
p < 0.01;
p < 0.05;
p < 0.001.
Multiple regression model of weight change in men with prostate cancer participating in a presurgical weight loss trial (n = 28).
| R | B | Standardized beta | Partial r | P value | |
|---|---|---|---|---|---|
| Weight change (kg), p < 0.001 | 0.792 | ||||
| Intercept | 2.60 | ||||
| Change in HR @ Stage 2 | 0.19 | 0.509 | 0.635 | 0.0005 | |
| Days on study | −0.08 | −0.453 | −0.589 | 0.0015 | |
| Change in caloric intake | 0.002 | 0.315 | 0.457 | 0.0189 |